Author

N. Ananthaswamy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

H. Batra· 3 shared J. Zhu· 3 shared S. Jain· 3 shared V. B. Rao· 3 shared A. Drelich· 2 shared A. K. Chopra· 2 shared J. Sha· 2 shared P. B. Kilgore· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

H. Batra

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine

J. Zhu, S. Jain, J. Sha, H. Batra, N. Ananthaswamy, P. B. Kilgore, E. Hendrix, Y. M. Hosakote, X. Wu, J. P. Olano, A. Kayode, C. L. Galindo, S. Banga, A. Drelich, V. Tat, , V. B. Rao

This paper develops a bacteriophage-based mucosal vaccine that induces strong immune responses and protects against SARS-CoV-2 and its variants without requiring needles or adjuvants.

bioRxiv · Apr 28, 2022Microbiology

Targeted Bacteriophage T4 Nanoparticles Reverse HIV-1 Latency in CD4+ Human T Cells

H. Batra, J. Zhu, S. Jain, N. Ananthaswamy, M. Mahalingam, P. Tao, C. Lange, S. Hill, C. Zhong, M. F. Kearney, H. Hu, F. Maldarelli, V. B. Rao

The paper shows that CD4-targeted bacteriophage T4 nanoparticles reactivate HIV-1 latency in CD4+ T-cells without global activation or cytokine storm.

bioRxiv · Jul 20, 2021 · PreprintImmunology

A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering

V. B. Rao, J. Zhu, N. Ananthaswamy, S. Jain, H. Batra, W.-C. Tang, D. A. Lewry, M. L. Richards, S. A. David, P. B. Kilgore, J. Sha, A. Drelich, C.-T. Tseng, A. K. Chopra

This paper develops a CRISPR-engineered bacteriophage T4 nanoparticle platform to create multiplex SARS-CoV-2 vaccine candidates, showing potent immune responses and protection in animal models.

bioRxiv · Jan 19, 2021Microbiology